Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
Mersana Therapeutics (NASDAQ: MRSN) announced it will report business updates and third quarter 2025 financial results for the period ended September 30, 2025 on Friday, November 14, 2025.
The company will host a conference call and live webcast on November 14, 2025 at 8:00 a.m. Eastern Time. Domestic dial-in is 833-255-2826, international dial-in is 412-317-0689. A replay of the webcast will be available on the Investors & Media section of www.mersana.com for approximately 90 days following the call.
Mersana Therapeutics (NASDAQ: MRSN) ha annunciato che riferirà aggiornamenti aziendali e i risultati finanziari del terzo trimestre 2025 per il periodo terminato il 30 settembre 2025 in venerdì 14 novembre 2025.
L'azienda ospiterà una conference call e una webcast in diretta il 14 novembre 2025 alle 8:00 a.m. Eastern Time. Il numero di accesso domestico è 833-255-2826, quello internazionale è 412-317-0689. Una replica della webcast sarà disponibile nella sezione Investitori & Media di www.mersana.com per circa 90 giorni dopo la chiamata.
Mersana Therapeutics (NASDAQ: MRSN) anunció que informará actualizaciones comerciales y los resultados financieros del tercer trimestre de 2025 para el periodo terminado el 30 de septiembre de 2025 en viernes, 14 de noviembre de 2025.
La empresa organizará una llamada de conferencia y webcast en vivo el 14 de noviembre de 2025 a las 8:00 a.m. hora del Este. La marcación nacional es 833-255-2826, la marcación internacional es 412-317-0689. Una reproducción del webcast estará disponible en la sección Inversores y Medios de www.mersana.com durante aproximadamente 90 días después de la llamada.
Mersana Therapeutics (NASDAQ: MRSN)가 2025년 3분기에 대한 2025년 9월 30일 종료 기간의 비즈니스 업데이트 및 재무실적을 2025년 11월 14일 금요일에 발표한다고 발표했습니다.
회사는 2025년 11월 14일 오전 동부 표준시 8:00에 컨퍼런스 콜 및 라이브 웹캐스트를 개최합니다. 국내 전화 접속 번호는 833-255-2826, 국제 전화 접속 번호는 412-317-0689입니다. 웹캐스트의 재방송은 콜 이후 약 90일 동안 www.mersana.com의 Investors & Media 섹션에서 이용 가능합니다.
Mersana Therapeutics (NASDAQ: MRSN) a annoncé qu'elle publiera des mises à jour commerciales et les résultats financiers du troisième trimestre 2025 pour la période se terminant le 30 septembre 2025 le vendredi 14 novembre 2025.
L'entreprise animera une conférence téléphonique et une webcast en direct le 14 novembre 2025 à 8 h 00, heure de l'Est. Le numéro d'appel national est 833-255-2826, le numéro d'appel international est 412-317-0689. Une rediffusion du webcast sera disponible dans la section Investisseurs et Médias de www.mersana.com pendant environ 90 jours après l'appel.
Mersana Therapeutics (NASDAQ: MRSN) gab bekannt, dass sie Geschäftsupdates und die Ergebnisse des dritten Quartals 2025 für den Zeitraum bis zum 30. September 2025 am Freitag, dem 14. November 2025 berichten wird.
Das Unternehmen wird am 14. November 2025 um 8:00 Uhr Eastern Time eine Konferenzschaltung und einen Live-Webcast abhalten. Die nationale Einwahl lautet 833-255-2826, die internationale Einwahl lautet 412-317-0689. Eine Wiedergabe des Webcasts wird im Bereich Investoren & Medien von www.mersana.com für ca. 90 Tage nach dem Anruf verfügbar sein.
Mersana Therapeutics (NASDAQ: MRSN) أعلنت أنها ستعرض تحديثات الأعمال والنتائج المالية للربع الثالث من 2025 للفترة المنتهية في 30 سبتمبر 2025 في الجمعة 14 نوفمبر 2025.
ستعقد الشركة مكالمة مؤتمريّة وبثًا حيًا عبر الويب في 14 نوفمبر 2025 الساعة 8:00 صباحًا بتوقيت شرق الولايات المتحدة. الرقم المحلي للدخول هو 833-255-2826، والرقم الدولي للدخول هو 412-317-0689. ستكون إعادة تشغيل البث متاحة في قسم المستثمرين ووسائل الإعلام في www.mersana.com لمدة حوالي 90 يومًا بعد المكالمة.
- None.
- None.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the third quarter ended September 30, 2025 on Friday, November 14, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for approximately 90 days.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that have generated a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at www.mersana.com.
Contact:
Mersana@argotpartners.com
FAQ
When will Mersana Therapeutics (MRSN) report Q3 2025 results?
What time is the Mersana (MRSN) conference call for Q3 2025?
How can investors access the Mersana (MRSN) Q3 2025 webcast?
What are the dial-in numbers for Mersana (MRSN) Q3 2025 earnings call?
How long will the Mersana (MRSN) webcast replay be available?
Will Mersana (MRSN) provide business updates during the Q3 2025 call?
